YL205 / MediLink - LARVOL DELTA

Case Report: Complete response to the novel NaPi2b-targeting ADC YL205 in heavily pretreated platinum-resistant ovarian cancer. (PubMed, Front Oncol) - "A 40-year-old woman with FIGO stage IVB, BRCA-wildtype HGSOC developed rapid multi-drug resistance following neoadjuvant chemotherapy, optimal cytoreduction, and progression on maintenance olaparib/bevacizumab, gemcitabine, and a USP1 inhibitor. By utilizing topoisomerase I inhibitors, agents like YL205 bypass microtubule-stabilization resistance induced by prior taxane exposure, while "bystander effects" address intratumoral heterogeneity. Longitudinal, biomarker-matched strategies and proactive toxicity management are essential to achieving deep tissue clearance in heavily pretreated HGSOC."

Journal • Platinum resistant • Hematological Disorders • High Grade Serous Ovarian Cancer • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor • BRCA • MUC16 • SLC34A2 • USP1

YL205, a novel anti-Napi2b antibody drug conjugate (ADC), in patients with ovarian cancer: Preliminary result from a first-in-human trial. (ASCO 2026) - P1/2 | "Previous therapies included bezacizumab (89.6%), PARP inhibitors (43.8%), and mirvetuximab soravtansine (2.1%). YL205 demonstrated a manageable safety profile in heavily pretreated ovarian cancer patients, with preliminary efficacy observed irrespective of NaPi2b expression intensity. The promising clinical data supports further investigation of this ADC in OC. Clinical trial information: NCT06459973."

ADC • Clinical • First-in-human • P1 data • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor • Thrombocytopenia • SLC34A2

Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors (AACR 2024) - "The highly stable nature of TMALIN linker, together with the high potency of the payload, likely mitigates the potential liability of this normal tissue expression. Based on these results, it demonstrates that YL205's advanced ADC design results in an increased therapeutic margin, and YL205 may help address unmet medical need in patients with NaPi2b-expressing tumors."

ADC • Preclinical • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • SLC34A2

YL205-CN-101-01: A Clinical Study of YL205 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=252 | Recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

YL205-CN-101-01: A Clinical Study of YL205 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=252 | Not yet recruiting | Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor